Cargando…

Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide

CONTEXT: Rare homozygous or biallelic variants in POMC, PCSK1, and LEPR can disrupt signaling through the melanocortin-4 receptor (MC4R) pathway, resulting in hyperphagia and severe early-onset obesity. In pivotal Phase 3 clinical trials, treatment with the MC4R agonist setmelanotide reduced hunger...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wabitsch, Martin, Farooqi, Sadaf, Flück, Christa E, Bratina, Natasa, Mallya, Usha G, Stewart, Murray, Garrison, Jill, van den Akker, Erica, Kühnen, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9070354/ https://www.ncbi.nlm.nih.gov/pubmed/35528826 http://dx.doi.org/10.1210/jendso/bvac057

Ejemplares similares

Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies
por: Wabitsch, Martin, et al.
Publicado: (2022)

ODP607 Long-term Efficacy of Setmelanotide in Patients With POMC or LEPR Deficiency Obesity
por: Clément, Karine, et al.
Publicado: (2022)

Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency
por: Kühnen, Peter, et al.
Publicado: (2022)

Timing of Onset of Adverse Events With Setmelanotide, an MC4R Agonist, in Patients With Severe Obesity Due to LEPR or POMC Deficiency
por: Clément, Karine, et al.
Publicado: (2021)

RF24 | PSUN96 Setmelanotide in Patients With Heterozygous POMC, LEPR, SRC1, or SH2B1 Obesity: Design of EMANATE – A Placebo-Controlled Phase 3 Trial
por: Wabitsch, Martin, et al.
Publicado: (2022)

OR10-1 Body Mass Index and Weight Reductions in Patients With Obesity Due to Heterozygous Variants in POMC, PCSK1, and LEPR After 1 Year of Setmelanotide
por: Farooqi, Sadaf, et al.
Publicado: (2022)

Beneficial Effects of Setmelanotide in a 5-Year-Old Boy With POMC Deficiency and on His Caregivers
por: Dubern, Beatrice, et al.
Publicado: (2023)

RF24 | PSUN91 Body Mass Index and Weight Reduction in Patients With SH2B1 Genetic Variant Obesity After One Year of Setmelanotide
por: Argente, Jesús, et al.
Publicado: (2022)

Hypothalamic CREB Regulates the Expression of Pomc-Processing Enzyme Pcsk2
por: Zanesco, Ariane Maria, et al.
Publicado: (2022)

Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome
por: Ervin, Claire, et al.
Publicado: (2023)

ODP605 Body Mass Index and Weight Reductions in Patients With SRC1 Genetic Variant Obesity After 1 Year of Setmelanotide
por: Martos-Moreno, Gabriel Á, et al.
Publicado: (2022)

A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation
por: Reininghaus, Nanina, et al.
Publicado: (2022)

IGF2, LEPR, POMC, PPARG, and PPARGC1 gene variants are associated with obesity-related risk phenotypes in Brazilian children and adolescents
por: Queiroz, E.M., et al.
Publicado: (2015)

Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome
por: Haws, Robert, et al.
Publicado: (2020)

Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet–Biedl syndrome: phase 3 trial results
por: Forsythe, Elizabeth, et al.
Publicado: (2023)

Structures of active melanocortin-4 receptor–Gs-protein complexes with NDP-α-MSH and setmelanotide
por: Heyder, Nicolas A., et al.
Publicado: (2021)

The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design
por: Haws, Robert M., et al.
Publicado: (2021)

La Lepre
Publicado: (1934)

Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
por: Collet, Tinh-Hai, et al.
Publicado: (2017)

Restoration of Lepr in β cells of Lepr null mice does not prevent hyperinsulinemia and hyperglycemia
por: D'souza, Anna M., et al.
Publicado: (2017)

Proopiomelanocortin (POMC) and psychodermatology
por: Millington, George W. M., et al.
Publicado: (2023)

ODP606 Long-term Efficacy of Setmelanotide in Patients With Bardet-Biedl Syndrome
por: Argente, Jesús, et al.
Publicado: (2022)

Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity
por: Trapp, Christine M., et al.
Publicado: (2023)

Obesity, POMC, and POMC-processing Enzymes: Surprising Results From Animal Models
por: Lindberg, Iris, et al.
Publicado: (2021)

Severe obesity and diabetes insipidus in a patient with PCSK1 deficiency()
por: Frank, Graeme R., et al.
Publicado: (2013)

FRI082 Impact Of Setmelanotide On Metabolic Parameters And Vital Signs In Patients With Hypothalamic Obesity
por: Jennifer Abuzzahab, M, et al.
Publicado: (2023)

Obesity and Hyperphagia With Increased Defective ACTH: A Novel POMC Variant
por: van der Valk, Eline S, et al.
Publicado: (2022)

FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial
por: Roth, Christian L, et al.
Publicado: (2023)

Characterization of a new animal model of metabolic syndrome: the DahlS.Z-Lepr(fa)/Lepr(fa) rat
por: Hattori, T, et al.
Publicado: (2011)

Steroid receptor coactivator-1 modulates the function of Pomc neurons and energy homeostasis
por: Yang, Yongjie, et al.
Publicado: (2019)

Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
por: Mallya, Usha G., et al.
Publicado: (2017)

SAT656 Weight Reduction After 6 Months Of Setmelanotide Treatment In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

Selective Restoration of Pomc Expression in Glutamatergic POMC Neurons: Evidence for a Dynamic Hypothalamic Neurotransmitter Network
por: Jones, Graham L., et al.
Publicado: (2019)

A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide
por: Haws, Robert, et al.
Publicado: (2021)

PREMATURE CARDIAC SENESCENCE IN DahlS.Z-Lepr(fa)/Lepr(fa) RATS AS A NEW ANIMAL MODEL OF METABOLIC SYNDROME
por: TAKAHASHI, KEIJI, et al.
Publicado: (2014)

Pomc-expressing progenitors give rise to antagonistic populations in hypothalamic feeding circuits
por: Padilla, Stephanie L., et al.
Publicado: (2010)

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
por: Ryan, Donna H.
Publicado: (2021)

Metformin Suppresses Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BL/KsJ-+Lepr(db)/+Lepr(db) Mice
por: Ohno, Tomohiko, et al.
Publicado: (2015)

The role of proopiomelanocortin (POMC) neurones in feeding behaviour
por: Millington, George WM
Publicado: (2007)

PERK in POMC neurons connects celastrol with metabolism
por: He, Zhenyan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4gdnnn15m9f0thqcdrnelcfsbn